

I. Hirao, et al
U.S.S.N. 09/787,196
Page 12

Attachment A

Lise-Lotte Gundersen, *Tetrahedron Letters*, Vo. 35, No. 19, pp. 3155-3158, 1994

6-Chloropuines and Organostannanes in Palladium Catalyzed Cross Coupling Reactions

3/6



Pergamon

Tetrahedron Letters, Vol. 35, No. 19, pp. 3155-3158, 1994

Elsevier Science Ltd
Printed in Great Britain
0040-4039/94 \$4.00+0.00

0040-4039(94)E0471-9

6-Chloropurines and Organostannanes in Palladium Catalyzed Cross Coupling Reactions

Lisa-Lotte Gundersen


Department of Chemistry, University of Oslo, P.O. Box 1047 Blindern, N-0315 Oslo,
and

Norwegian College of Pharmacy, Svan Oddalsvei 8, N-0950 Oslo, Norway

Abstract: Carbon-carbon bond formation in the purine 6-position can easily be accomplished by palladium catalyzed cross coupling between 6-chloropurines and organostannanes without protection of the purine ring *NH* function. This technique provides a convenient route to fused bicyclics.

Kinetin (6-furfurylthiouracine) and related 6-substituted purines, called cytokinins, are known to stimulate cell growth and cell division in plants.¹ Several purines with potent cytokinin activity contain a 6-allyl or 6-alkyl substituent.² An efficient route to these compounds would be transition metal catalyzed cross coupling of organometallic reagents with readily available 6-halopurines. For instance, 6-chloropurine **1a** (Scheme 1) is commercially available and the substance can also easily be prepared on a large scale.³ Because of the acidity of the purine ring *NH* function (pKa of 6-chloropurine: 7.88),⁴ organometallic reagents with low basicity are desired. Examples of transition metal mediated couplings of purines with a free *NH* function are restricted to palladium catalyzed Heck coupling of terminal alkynes with halopurines,⁵ and nickel catalyzed coupling of methylthiouracine with Grignard reagents in which case 2.5 equivalents of the basic Grignard reagents were required.⁶ Palladium catalyzed cross coupling between heteroaryl halides and organotin derivatives is an established method for carbon-carbon bond formation in heterocycles,⁷ but the scope of this method is rarely investigated in the purine ring system.⁸ Only coupling reactions employing *N*-9 alkylated iodopurines are reported. In fact, very recently the first two examples of coupling in the purine 6-position appeared.^{9a}

Palladium catalyzed cross coupling of organostannanes **2a - c** with 6-chloropurines **1a - b** has been studied (Scheme 1, Table 1).



Scheme 1









2004年 4月30日 19時10分 友成商事株式会社

NO. 4457 P. 7/9

4/6

3156

Table 1. Pd-Catalyzed Coupling between Organotinanes and Chloropyrimidines.

Pyrimidine 1	Organotinane 2	React. time (h)	Temp. (°C)	Product 3	Yield (%)
1a	$\text{PhCH}_2\text{-CH(SnBu}_3\text{)}_2$ 2a ¹¹	20	80	 3a ¹⁴	84
1b	2a	45	80	 3b	75
1a	$\text{CH}_3\text{-C(=O)OSnBu}_3$ 2b	20	80	 3c	58
1a	PhSnBu_3 2c	20	100	 3d ¹⁵	81
1b	2c	45	100	 3e	73
1a	$(2\text{-thienyl})_2\text{SnBu}_3$ 2d ¹²	20	90	 3f	81
1b	2d	45	90	 3g	76
1a	$\text{PhCH}_2\text{-SnBu}_3$ 2e ¹³	20	130	 3h ¹⁴	36

5/6

3157

Organostannanes are known to tolerate a wide variety of functional groups on the coupling partners,⁹ and the stannane **2a** - a coupled with the relatively acidic purines **1a** and **1b**. Bis(triphenylphosphine)palladium(II) dichloride was found to be a suitable catalyst.¹⁰

This methodology makes purines with allyl-, aryl-, and heteroaryl substituents in the 6-position easily accessible, and the potent cytokinetic 6-*trans*-styrylpurine **3a**, was prepared in a one-step procedure superior to the methods reported earlier.¹⁴ Even the much less reactive benzyl(dibutyl)stannane **2c** participated in the coupling to give the 6-benzylpurine **3b** in a moderate yield.

The 6-aryl purines **3a** - **b** were prepared from a 1 : 9 mixture of *cis* and *trans* styrylin reagent **2a** (1.3 equiv.), but only the *trans* products were formed as judged by ¹H NMR of the crude products, indicating a slightly higher reactivity of the *trans* organotin reagent. Isomerization of the alkenes in the reaction can not be excluded, but retention of the allylstannane double bond geometry is generally observed in palladium catalyzed cross couplings.⁹

The order of reactivity of aryl halides in palladium mediated cross coupling reactions is found to be Ar-I > Ar-Br >> Ar-Cl.⁹ Only aryl chlorides with an electron deficient *para* carbon will participate in the reaction. For instance, 2- and 4-chloropyridines are shown to be sufficiently activated for the coupling to occur.⁷ In earlier reports, iodopurines have been employed in couplings with organostannanes,⁸ and even though the yields in Heck couplings of 6-chloropurines are rather moderate compared to the corresponding iodopurines,^{9,15} this present study shows that the 6-chloropurines **1a** and **1b** are reactive enough to give high yields of the coupling products in palladium catalyzed reactions with allyl- and aryltin derivatives. This is a great advantage since iodopurines are less available. In fact, iodopurines are often prepared from the corresponding chloropurines.^{15,16}

The lower reaction rate observed in the couplings of 2-amino-6-chloropurine **1b** compared to 6-chloropurine **1a** might be ascribed to higher electron density in the former ring, making the compound less activated for nucleophilic attack from Pd(0).⁹ Initially, the coupling reactions with the 2-amino compound **1b** were carried out in a much less concentrated solution due to poor solubility, but reactions of the purine **1a** were not so significantly affected by concentration.

In summary, carbon-carbon bond formation in the purine 6-position can easily be accomplished by palladium catalyzed cross coupling of readily available 6-chloropurines with organostannanes without protection of the purine ring NH function. This technique provides an efficient route to potent cytokinines.

References and Notes

1. Miller, C. O. *Ann. Rev. Plant Physiol.* 1961, 12, 395-408.
2. a) Henderson, T. R.; Frihart, C. R.; Leonard, N. L.; Schmitz, R. Y.; Skoog, P. *Phytochemistry* 1975, 14, 1687-1690. b) Nishikawa, S.; Kumazawa, Z.; Mizutani, H.; Kashimura, N. *Agria. Biol. Chem.* 1986, 50, 1089-1091. c) Nishikawa, S.; Kumazawa, Z.; Kashimura, N.; Mizutani, H.; Kondo, H. *Agria. Biol. Chem.* 1985, 49, 3353-3354.
3. Branan, A. G.; Robins, R. K. *J. Appl. Chem.* 1962, 12, 432-437.
4. Hartin, G. B.; Chapman, N. B. *J. Chem. Soc.* 1963, 3017-3022.
5. Koyama, S.; Kumazawa, Z.; Kashimura, N. *Nucl. Acids Res., Symp. Ser.* 1982, 11, 41-44.
6. Sugimura, H.; Takai, H. *Bull. Chem. Soc. Jpn.* 1983, 56, 664-666.
7. For recent reviews, see for instance: a) Kalinin, V. N. *Synthesis* 1992, 413-432. b) Undheim, K.; Beumiche, T. *Acta Chem. Scand.* 1993, 47, 107-121.
8. a) Nair, V.; Turner, G. A.; Chamberlain, S. D. *J. Am. Chem. Soc.* 1987, 109, 7223-7224. b) Nair, V.; Bueger, G. S. *J. Am. Chem. Soc.* 1989, 111, 8502-8504. c) Nair, V.; Purdy, D. R.; Sells, T. B. *J. Chem. Soc., Chem. Commun.* 1989, 878-879. d) Nair, V.; Purdy, D. F. *Tetrahedron* 1991, 47, 365-382. e) Van Aartsen, A. A.; Mamun, P.; Weyss, N. J.; Ikeda, S.; De Clercq, E.; Herkowitz, P. A. *J. Med. Chem.* 1993, 36, 2938-2942.
9. a) Sells, J. K. *Pure Appl. Chem.* 1985, 57, 1771-1780. b) Sells, J. K. *Angew. Chem.* 1986, 98, 504-519.

2004年 4月30日 19時10分

夏小計事務

NO. 4457 P. 9/9

6/6

3158

10. The organostannane **2** (1.3 mmol) was added to a mixture of bis(triphenylphosphine)palladium(II) dichloride (39 mg, 0.03 mmol) and 6-chloropurine **1a** (1.0 mmol) in dry DMF (5 ml) or 2-amino-6-chloropurine **1b** (1.0 mmol) in DMF (15 ml) and the mixture was stirred under N_2 at the temperature indicated in Table 1, before the reaction mixture was filtered and evaporated, and the residue was washed with ether. The crude product was purified by flash chromatography or recrystallization. **3a**: 1H NMR (DMSO- d_6) δ 6.32 (s, 2H), 7.4–7.5 (m, 4H), 7.7 (m, 2H), 8.10 (s, 1H), 8.25 (d, J 16 Hz, 1H), 12.6 (br, 1H). MS (EI): 237 (2, M^+), 207 (100). **3c**: 1H NMR (DMSO- d_6) δ 1.46 (t, J 7 Hz, 3H), 4.15 (s, J 7 Hz, 2H), 4.77 (d, J 2 Hz, 1H), 5.68 (d, J 2 Hz, 1H), 8.77 (s, 1H), 8.91 (s, 1H), 13.6 (br, 1H). MS (EI): 190 (100, M^+). **3e**: 1H NMR (DMSO- d_6) δ 6.58 (s, 2H), 7.5–7.6 (m, 3H), 8.11 (s, 1H), 8.7–8.8 (m, 2H), 12.7 (br, 1H). MS (EI): 211 (100, M^+). **3f**: 1H NMR (DMSO- d_6) δ 7.36 (m, 1H), 7.92 (m, 1H), 8.66 (m, 2H), 8.84 (s, 1H), 13.7 (br, 1H). MS (EI): 202 (100, M^+). **3g**: 1H NMR (DMSO- d_6) δ 6.40 (s, 2H), 7.28 (m, 1H), 7.80 (m, 1H), 8.12 (s, 1H), 8.57 (m, 1H), 12.7 (br, 1H). MS (EI): 217 (100, M^+).
11. Labadie, J. W.; Sells, J. K. *J. Am. Chem. Soc.* 1983, 105, 6125–6137.
12. Pinhey, J. T.; Roche, E. G. *J. Chem. Soc., Perkin Trans. 1* 1988, 2415–2421.
13. Davison, A. G.; Roberts, B. P.; Smith, J. M. *J. Chem. Soc., Perkin Trans. 2* 1972, 2221–2224.
14. a) Hampson, A. *J. Heterocyclic Chem.* 1974, 11, 255–256. b) Taylor, E. C.; Martin, S. R. *J. Am. Chem. Soc.* 1974, 96, 8095–8102.
15. Tanji, K.-I.; Higashino, T. *Chem. Pharm. Bull.* 1968, 36, 1935–1941.
16. a) Kilco, G. B.; Hinchings, G. H. *J. Am. Chem. Soc.* 1956 78, 3508–3510. b) McKenzie, T. C.; Epsman, J. W. *J. Org. Chem.* 1982, 47, 4881–4884.

(Received in UK 29 December 1993; accepted 4 March 1994)